Business Context and Reporting Period
Company: American Healthcare REIT, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 3, 2023
Event: Entry into a Material Definitive Agreement (Membership Interest Purchase Agreement/Option Agreement).
On November 3, 2023, the Company and its subsidiary GAHC3 Trilogy JV, LLC ("Buyer") entered into an agreement with NorthStar Healthcare Income Operating Partnership, LP and its subsidiary Trilogy Holdings NT-HCI, LLC ("Seller"). The agreement grants the Buyer an option to purchase all minority membership interests held by the Seller in the Company's subsidiary, Trilogy REIT Holdings, LLC ("Trilogy Holdings"). If exercised, the Company will own 100% of Trilogy Holdings.
Key Financial Metrics and Transaction Terms
This filing details a potential acquisition rather than reporting standard periodic financial results (revenue, profit, cash flow). Key financial terms of the Option Agreement include:
- Purchase Price (Cash Only):
- $240.5 million if closed on or before March 31, 2024.
- $247.0 million if closed between April 1, 2024, and December 31, 2024.
- $260.0 million if closed on or after January 1, 2025.
- Supplemental Payment: Up to $25,600 per day for the period between July 1, 2023, and the Closing Date. If closed on September 30, 2025, this could total approximately $21 million.
- Alternative Consideration (Cash + Stock): Buyer may elect to pay a minimum cash amount ($24.05M - $26.0M depending on closing date) plus 9,360,000 shares of new Series A Cumulative Convertible Preferred Stock (aggregate liquidation preference of $234.0 million).
- Termination Fees: Ranging from $3.9 million to $15.6 million depending on extension options exercised and whether a "Qualifying IPO" has occurred.
- Extension Fees: $7.8 million for the first extension (to March 30, 2025) and an additional $3.9 million for the second extension (to September 30, 2025).
Material Changes and Conditions
The filing does not report changes in historical financial performance but outlines material conditions precedent to the transaction:
- Capital Raise Requirement: If the transaction involves issuing Convertible Preferred Stock, the Company must receive at least $200.0 million in proceeds from equity offerings or asset sales after October 20, 2023.
- Listing Requirement: The Company must list its Common Stock on a national securities exchange.
- Extension Options: The "outside date" for closing is initially September 30, 2024, but can be extended to September 30, 2025, subject to pre-payment of termination fees.
- Ownership Waiver: The Board will grant a waiver to Charter Ownership Limits (currently 9.9%) to allow the Seller to hold the Convertible Preferred Stock.
Guidance, Risks, and Contingencies
Management Commentary and Outlook: The Company has issued a press release regarding the agreement. The transaction is contingent on the Buyer exercising the option and satisfying closing conditions. The filing includes standard forward-looking statements disclaiming assurance that expectations will be attained.
Risks and Contingencies:
- Transaction Failure: The Buyer may not elect to exercise the purchase option, or may fail to satisfy conditions (e.g., raising $200M in capital).
- Termination Costs: The Company may be required to pay cash termination fees ranging from $3.9 million to $15.6 million if the agreement is terminated under certain circumstances.
- Indemnification: Obligations are subject to a $1.95 million "basket" (deductible) and a $19.5 million "cap".
- Put Rights: If Convertible Preferred Stock is issued, the Seller may have the right to require the Company to redeem shares for cash under certain instances.
Investor Verification Checklist
- Verify the Company's ability to raise the required $200.0 million in proceeds from equity or asset sales if the stock consideration option is chosen.
- Confirm the status of the Company's Common Stock listing on a national securities exchange.
- Monitor the timeline for the "outside date" (initially Sept 30, 2024) and any announcements regarding the exercise of extension options.
- Review the full text of the Membership Interest Purchase Agreement (Exhibit 10.1) for specific representations and warranties not detailed in this summary.
- Assess the potential dilution impact of issuing 9,360,000 shares of Convertible Preferred Stock if the mixed consideration option is utilized.